Lebenslauf Dr. Anke Fuchs
Positions
| since 2024 |
Qualified Person acc. to German drug law §14 AMG Scientific Lead of the Good Manufacturing Practice (GMP) Facility, Center for Regenerative Therapies Dresden |
| since 2023 | TUD Young Investigator |
| since 2021 | CAR T working group co-leader, BMFTR Cluster4Future “SaxoCell” - Saxonian precision therapy cluster for living drugs |
| since 2019 |
Mildred-Scheel-Nachwuchszentrum (MSNZ) and Center for Regenerative Therapies Dresden (CRTD) Research group leader |
| from 2015 |
Project leader Clinical Translation CRTD/Medical Clinic I, University Hospital Dresden |
| 2013-2014 |
Postdoctoral scientist, CRTD (Group Ezio Bonifacio; Topic: autoimmunity, type 1 diabetes) |
| 2007 | Industrial Placement at R&D department, Proimmune, Oxford, UK |
Education
| 2008-2012 | Doctorate (PhD) (Group Ezio Bonifacio), Dresden within the DIGS-BB |
| 2001-2008 | Technical Biology Studies at University of Stuttgart |
| 2005-2006 | Undergraduate Thesis, Auckland Cancer Society Research Center, New Zealand |
Honors
| 2017/2018 | Fellow of the Maria-Reiche Mentoring Programe for female scientists, TU Dresden |
| 2017 |
Young Investigator Award of the International Society of Cellular Therapy (ISCT) |
| 2012 |
Best dissertation award, CRTD |
| 2005/2006 | Stipend from the Landesstiftung foundation of the federal state Baden-Württemberg for for a research stay at the University of Auckland, New Zealand |
Memberships
|
German Cancer Consortium (DKTK) |
|
National Center for Tumor Diseases (NCT) |
|
International Society for Cell and Gene Therapy (ISCT) |
|
International Society for Stem Cell Research (ISSCR) |
|
German Society for Gene Therapy (DG-GT e.V.) |
|
German Society for Immunology (DGfI) |
Funding
| 2026-2027 |
DKH Mildred Scheel Early Career Center: Development of modified, umbilical cord blood-derived UniCAR T cells for T-ALL |
| 2026-2027 | ForTra gGmbH | Der EKFS |
| 2025-2026 | EU/EFRE ATORM2Clinic: Entwicklung, Validierung und Genehmigung des GMP-konformen Herstellungsprozesses für das organoide Zellprodukt ATORM-C in Deutschland |
| 2024-2027 |
BMFTR Cluster4Future SaxoCell: UniK-T: Universelle, KI-geführte designer CAR-T-Zell-Therapie gegen Tumor- (UniK Tackle), Entzündungs- und Autoimmunerkrankungen (UniK Tame) |
| 2022-2024 |
BMBF GoBio Initial: Makrophagen 2.0 |
| 2021-2024 | BMBF Cluster4Future SaxoCell: AlloCARTreg |
| 2020 |
MeDDrive "Deep immune profiling after T regulatory cell therapy in chronic graft-versus-host disease" |
| 2019-2025 |
DKH Mildred Scheel Early Career Center: Junior Research Group “Advanced Cellular Therapeutics” |